November 02, 2015.
Shire (Dublin, Ireland) and Dyax Corp. (Burlington, MA) today announced that Shire will acquire Dyax for $37.30 in cash per Dyax share, for aggregate upfront consideration of approximately $5.9 billion. The acquisition furthers Shire’s strategy to become a leading global biotech. Dyax is a biotechnology company primarily focused on the development of plasma kallikrein (pKal) inhibitors for the treatment of HAE, a debilitating and sometimes life-threatening rare genetic disease. Its most advanced clinical program is DX-2930, which has received fast track, breakthrough therapy, and orphan drug designations from FDA and has also received orphan drug status in the EU. It is expected to enter Phase 3 clinical trials by year-end 2015. If approved for the prevention of Type 1 and Type 2 HAE, DX-2930 could reportedly generate estimated annual global sales of up to $2.0 billion.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.